ArticleCureus2026
Genomic Surveillance of SARS-CoV-2 Variants Circulating in Rajasthan in 2025.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe COVID-19 pandemic, caused by the SARS-CoV-2 virus, has undergone significant evolutionary changes since its onset, resulting in the emergence of multiple variants with distinct genetic profiles and public health implications. Numerous genetic modifications have occurred in the virus since it first appeared, leading to the development of several variants with varying degrees of virulence, transmissibility, and immunological escape potential. MATERIALS AND
methodsA total of 602 throat/nasopharyngeal swabs of SARS-CoV-2-positive patients were received at Sawai Man Singh Medical College (SMSMC), Jaipur, India, from April 30, 2025, to September 5, 2025, for next-generation sequencing, of which 373 samples having a Ct value ≤ 25 were further processed for sequencing.
resultsAmong the 373 lineages identified, XFG was the predominant lineage and was detected in 182 (48.8%) cases, including XFG (85), XFG.3 (95), and XFG.3.1 (2). Other lineages identified were PY.1 (65, 17.43%), LF.7 and its sublineages (61, 16.35%), JN.1 and its sublineages (23, 6.17%), PY.2 (23, 6.17%), BA.2 and its sublineages (8, 2.14%), PL.1.1 (3, 0.8%), LP.8.1 (2, 0.53%), NB.1.8.1 (2, 0.53%), XFC.1 (1, 0.27%), XFJ (1, 0.27%), PQ.7 (1, 0.27%) and IN.1.16.1 (1, 0.27%). Among the total positive cases identified, 55.76% were males and 44.24% were females. Regarding age distribution, 10.19% were aged <18 years, 68.90% were aged 19-59 years, and 20.91% were aged ≥60 years. Overall, 21.18% of cases were asymptomatic, whereas 78.82% were symptomatic. Reinfection was observed in 28.95% (108) of cases. Most positive cases were reported from the Jaipur district. The majority of positive cases (88.47%, 330) had already been vaccinated. Comorbidities or other underlying conditions were present in 25.74% (96) of patients. Hospitalization was required in 25.47% (95) of cases, and death due to COVID was reported in three cases.
conclusionThe highest upsurge in COVID cases during the study period was due to the XFG variant, which is a recombinant hybrid of the LF.7 and LP.8.1.2 Omicron subvariants. Continuous genomic surveillance helps in detecting real-time viral recombination and mapping spike protein mutations that lead to the emergence of such variants. Genomic surveillance revealed a wide range of SARS-CoV-2 variants in Rajasthan, with implications for public health response and vaccination strategies. The study underscores the critical importance of sustained genomic surveillance programs in Rajasthan to track viral evolution in near real-time, mitigate transmission risks, and strengthen pandemic preparedness at both regional and national levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.